Top-Rated StocksTop-Rated Cabaletta Bio (CABA) Stock Price, News & Analysis $16.23 +0.24 (+1.50%) (As of 12/8/2023 08:56 PM ET) Add Compare Share Share Today's Range$15.35▼$16.5650-Day Range$12.22▼$18.7052-Week Range$5.11▼$19.34Volume983,100 shsAverage Volume662,693 shsMarket Capitalization$695.44 millionP/E RatioN/ADividend YieldN/APrice Target$27.64 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Cabaletta Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside70.3% Upside$27.64 Price TargetShort InterestHealthy11.81% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.23Based on 2 Articles This WeekInsider TradingSelling Shares$340,230 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.59) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsMedical Sector183rd out of 942 stocksBiological Products, Except Diagnostic Industry31st out of 157 stocks 4.5 Analyst's Opinion Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.64, Cabaletta Bio has a forecasted upside of 70.3% from its current price of $16.23.Amount of Analyst CoverageCabaletta Bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.81% of the outstanding shares of Cabaletta Bio have been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Cabaletta Bio has recently decreased by 19.43%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CABA. Previous Next 3.5 News and Social Media Coverage News SentimentCabaletta Bio has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cabaletta Bio this week, compared to 2 articles on an average week.Search Interest19 people have searched for CABA on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat Follows12 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $340,230.00 in company stock.Percentage Held by Insiders12.33% of the stock of Cabaletta Bio is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cabaletta Bio are expected to decrease in the coming year, from ($1.59) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -9.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -9.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 4.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cabaletta Bio Stock (NASDAQ:CABA)Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More CABA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CABA Stock News HeadlinesDecember 10, 2023 | seekingalpha.comBuy Cabaletta Bio's Promising SLE TreatmentDecember 3, 2023 | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) Shares Gap Down to $16.05December 11, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 2, 2023 | americanbankingnews.comCabaletta Bio, Inc. to Post FY2023 Earnings of ($1.61) Per Share, William Blair Forecasts (NASDAQ:CABA)December 1, 2023 | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) Research Coverage Started at William BlairNovember 28, 2023 | uk.finance.yahoo.comCabaletta Bio, Inc. (CABA)November 28, 2023 | marketwatch.comCabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T DrugsNovember 28, 2023 | msn.comCabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapyDecember 11, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 28, 2023 | finance.yahoo.comCabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNovember 27, 2023 | msn.comCabaletta Bio (CABA) Price Target Increased by 8.76% to 30.09November 15, 2023 | markets.businessinsider.comCantor Fitzgerald Maintains Overweight Rating for Cabaletta Bio: Here's What You Need To KnowNovember 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vertex (VERX) and Cabaletta Bio (CABA)November 10, 2023 | bizjournals.comLab Notes: Cabaletta Bio gets FDA nod to advance new drug; South Jersey firm raises $3.5MNovember 9, 2023 | msn.comCabaletta Bio GAAP EPS of -$0.37 beats by $0.04November 9, 2023 | finance.yahoo.comCabaletta Bio Inc (CABA) Reports Q3 2023 Financial Results and Business ProgressNovember 9, 2023 | benzinga.comCabaletta Bio: Q3 Earnings InsightsNovember 9, 2023 | finance.yahoo.comCabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 6, 2023 | marketwatch.comCabaletta Bio Gets FDA OK to Study CABA-201 in Generalized Myasthenia GravisNovember 6, 2023 | markets.businessinsider.comCabaletta Bio Gets FDA's Nod For CABA-201 INDA For Generalized Myasthenia GravisNovember 6, 2023 | finance.yahoo.comCabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia GravisNovember 6, 2023 | finance.yahoo.comCellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle PlatformNovember 1, 2023 | msn.comCabaletta Bio (CABA) Price Target Increased by 11.47% to 27.67October 30, 2023 | finance.yahoo.comCabaletta Bio to Participate in Multiple Upcoming Investor Conferences in NovemberOctober 25, 2023 | msn.comCantor starts Cabaletta at overweight, cites "strong" position in CART-T drugsOctober 24, 2023 | msn.comCantor Fitzgerald Initiates Coverage of Cabaletta Bio (CABA) with Overweight RecommendationOctober 24, 2023 | markets.businessinsider.com7 Analysts Have This to Say About Cabaletta BioSee More Headlines Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/11/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CABA CUSIPN/A CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees92Year FoundedN/APrice Target and Rating Average Stock Price Target$27.64 High Stock Price Target$50.00 Low Stock Price Target$10.00 Potential Upside/Downside+70.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.05% Return on Assets-43.21% Debt Debt-to-Equity RatioN/A Current Ratio15.65 Quick Ratio15.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.60 per share Price / Book4.51Miscellaneous Outstanding Shares42,849,000Free Float37,566,000Market Cap$695.44 million OptionableNot Optionable Beta2.42 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Steven A. Nichtberger M.D. (Age 62)Co-Founder, Chairman, CEO & President Comp: $970.6kDr. Gwendolyn K. Binder Ph.D. (Age 48)President of Science & Technology Comp: $692.99kDr. David J. Chang FACR (Age 60)M.D., M.P.H., Chief Medical Officer Comp: $676.74kDr. Michael C. Milone M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardDr. Aimee Payne M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardMr. Anup Marda M.B.A. (Age 46)Chief Financial Officer Comp: $548.2kDr. Samik Basu M.D.Chief Scientific OfficerMr. Michael Gerard J.D. (Age 43)General Counsel & Secretary Ms. Heather Harte-Hall M.Sc.Chief Compliance OfficerMs. Martha O'ConnorChief Human Resources OfficerMore ExecutivesKey CompetitorsNovavaxNASDAQ:NVAXAnavex Life SciencesNASDAQ:AVXLHilleVaxNASDAQ:HLVXImmaticsNASDAQ:IMTXAutolus TherapeuticsNASDAQ:AUTLView All CompetitorsInsiders & InstitutionsCitigroup Inc.Bought 42,078 shares on 12/6/2023Ownership: 0.116%Wellington Management Group LLPBought 246,570 shares on 12/1/2023Ownership: 0.575%Deutsche Bank AGBought 9,692 shares on 11/24/2023Ownership: 0.049%Comerica BankBought 2,028 shares on 11/21/2023Ownership: 0.005%The Manufacturers Life Insurance Company Bought 2,761 shares on 11/15/2023Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions CABA Stock Analysis - Frequently Asked Questions Should I buy or sell Cabaletta Bio stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CABA shares. View CABA analyst ratings or view top-rated stocks. What is Cabaletta Bio's stock price target for 2024? 10 analysts have issued 1-year price targets for Cabaletta Bio's stock. Their CABA share price targets range from $10.00 to $50.00. On average, they predict the company's stock price to reach $27.64 in the next twelve months. This suggests a possible upside of 70.3% from the stock's current price. View analysts price targets for CABA or view top-rated stocks among Wall Street analysts. How have CABA shares performed in 2023? Cabaletta Bio's stock was trading at $9.25 at the beginning of the year. Since then, CABA stock has increased by 75.5% and is now trading at $16.23. View the best growth stocks for 2023 here. Are investors shorting Cabaletta Bio? Cabaletta Bio saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 5,060,000 shares, a drop of 19.4% from the October 31st total of 6,280,000 shares. Based on an average trading volume of 788,600 shares, the days-to-cover ratio is currently 6.4 days. View Cabaletta Bio's Short Interest. When is Cabaletta Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our CABA earnings forecast. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) announced its earnings results on Thursday, November, 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.02. What ETFs hold Cabaletta Bio's stock? ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Invesco DWA SmallCap Momentum ETF (DWAS). What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE). When did Cabaletta Bio IPO? (CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO. Who are Cabaletta Bio's major shareholders? Cabaletta Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Fred Alger Management LLC (9.94%), Lynx1 Capital Management LP (4.91%), Redmile Group LLC (4.14%), Jennison Associates LLC (3.57%), Invesco Ltd. (1.99%) and Northern Trust Corp (0.70%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am. View institutional ownership trends. How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CABA) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.